12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MyoCell: Phase III started

Bioheart began the double-blind, placebo-controlled, North and South American Phase III MIRROR trial to evaluate MyoCell in up to 126 patients. Bioheart said FDA also placed a hold on its request for...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >